BRO vs ALNY Comparison

Brown & Brown Inc is a diversified insurance agency, wholesale brokerage, insurance programs, and service. The Company markets and sells insurance products and services, in the property, casualty, and employee benefits areas. It provides customers with non-investment insurance contracts, as well as other targeted, customized risk management products and services. It has four reportable segments; the Retail segment; the Programs segment; the Wholesale Brokerage segment and; the Services segment. It generates the majority of its revenue from the Retail segment which provides insurance products and services to commercial, public and quasi-public, and Others through automobile dealer services F&I businesses. Its geographic area is U.S., U.K., the Republic of Ireland, Canada, and Others.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.